Special Issue "Drugs Repurposing for the Treatment of Bacterial Infections"
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 51687
Interests: antimicrobial resistance; bacterial pathogenesis; antibiotics; repurposing drug; non-traditional approaches
Special Issues, Collections and Topics in MDPI journals
Multidrug-resistant (MDR) pathogens pose a well-recognized global health threat that demands effective solutions: in fact, the situation is deemed a global priority by the World Health Organization and the European Centre for Disease Prevention and Control. Therefore, the development of new antimicrobial therapeutic strategies requires immediate attention to avoid the 10 million deaths predicted to occur by 2050 as a result of MDR bacteria. The repurposing of drugs as therapeutic alternatives for infections has recently gained renewed interest. As drugs approved by the United States Food and Drug Administration, information about their pharmacological characteristics in preclinical and clinical trials is available. Therefore, the time and economic costs required to evaluate these drugs for other therapeutic applications, such as the treatment of bacterial infections, are mitigated. The goal of this Special Issue is to provide an overview of the scientific evidence on potential non-antimicrobial drugs targeting bacteria. In particular, we aim to: (i) List the approved drugs identified in drug screens as potential alternative treatments for infections caused by MDR bacteria; (ii) Review their mechanisms of action against bacteria; (iii) Summarize the outcome of preclinical and clinical trials investigating approved drugs that target these bacteria.
Dr. Younes Smani
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- repurposing drugs
- antimicrobial resistance